Cargando…
Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial
Hepatoblastoma (HB) is the most common liver tumor in children, and the main treatment for HB is currently surgery. Studies have shown that transcatheter arterial chemoembolization (TACE) combined with high intensity focused ultrasound (HIFU) has significant efficacy, but there are relatively few st...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726394/ https://www.ncbi.nlm.nih.gov/pubmed/36482636 http://dx.doi.org/10.1097/MD.0000000000032022 |
_version_ | 1784844770949988352 |
---|---|
author | Tang, Xinliang He, Xiaobing Jiang, Han |
author_facet | Tang, Xinliang He, Xiaobing Jiang, Han |
author_sort | Tang, Xinliang |
collection | PubMed |
description | Hepatoblastoma (HB) is the most common liver tumor in children, and the main treatment for HB is currently surgery. Studies have shown that transcatheter arterial chemoembolization (TACE) combined with high intensity focused ultrasound (HIFU) has significant efficacy, but there are relatively few studies on TACE combined with HIFU in China. OBJECTIVE: To investigate the effect of using HIFU combined with TACE on patients’ liver function impairment and immune function in pediatric HB patients and to analyze the effectiveness and safety. MATERIALS AND METHODS: The clinical data of 110 unresectable pediatric HB patients treated in our hospital from December 2019 to December 2021 were selected as the subjects and divided into 2 groups. The comparison group was treated with TACE, and the combination group was treated with HIFU on the basis of the comparison group. The differences in immune function, survival, treatment side effects and clinical efficacy between the 2 groups were observed. RESULTS: In the combined group, the 1-year survival rate was 100%, the 3-year survival rate was 84.0%, the 5-year survival rate was 16.0%; while in comparison group, it was 82%, 16%, 0%, respectively. The ratio of CD4(+)/CD8(+) in the combined group were significantly higher than in the comparison group after treatment (P < .05). Granulocytopenia, mucositis, thrombocytopenia, and cardiac and renal toxicity were significantly lower in the combined group than in the comparison group, and the effective rate of the combined group was 98.00% which was significantly higher than that of the control group (76.00%) (P < .05). CONCLUSION: Comparative study of HB in children treated with HIFU combined with TACE is more effective, effectively improving the immune level of patients, significantly increasing the remission rate, which can improve the tumor necrosis and improve the survival quality of patients, and is a better choice for HB in children. |
format | Online Article Text |
id | pubmed-9726394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97263942022-12-09 Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial Tang, Xinliang He, Xiaobing Jiang, Han Medicine (Baltimore) 4100 Hepatoblastoma (HB) is the most common liver tumor in children, and the main treatment for HB is currently surgery. Studies have shown that transcatheter arterial chemoembolization (TACE) combined with high intensity focused ultrasound (HIFU) has significant efficacy, but there are relatively few studies on TACE combined with HIFU in China. OBJECTIVE: To investigate the effect of using HIFU combined with TACE on patients’ liver function impairment and immune function in pediatric HB patients and to analyze the effectiveness and safety. MATERIALS AND METHODS: The clinical data of 110 unresectable pediatric HB patients treated in our hospital from December 2019 to December 2021 were selected as the subjects and divided into 2 groups. The comparison group was treated with TACE, and the combination group was treated with HIFU on the basis of the comparison group. The differences in immune function, survival, treatment side effects and clinical efficacy between the 2 groups were observed. RESULTS: In the combined group, the 1-year survival rate was 100%, the 3-year survival rate was 84.0%, the 5-year survival rate was 16.0%; while in comparison group, it was 82%, 16%, 0%, respectively. The ratio of CD4(+)/CD8(+) in the combined group were significantly higher than in the comparison group after treatment (P < .05). Granulocytopenia, mucositis, thrombocytopenia, and cardiac and renal toxicity were significantly lower in the combined group than in the comparison group, and the effective rate of the combined group was 98.00% which was significantly higher than that of the control group (76.00%) (P < .05). CONCLUSION: Comparative study of HB in children treated with HIFU combined with TACE is more effective, effectively improving the immune level of patients, significantly increasing the remission rate, which can improve the tumor necrosis and improve the survival quality of patients, and is a better choice for HB in children. Lippincott Williams & Wilkins 2022-12-02 /pmc/articles/PMC9726394/ /pubmed/36482636 http://dx.doi.org/10.1097/MD.0000000000032022 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4100 Tang, Xinliang He, Xiaobing Jiang, Han Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial |
title | Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial |
title_full | Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial |
title_fullStr | Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial |
title_full_unstemmed | Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial |
title_short | Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial |
title_sort | efficacy and safety of hifu in combination with tace in unresectable pediatric hb: a randomized, controlled, single-center clinical trial |
topic | 4100 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726394/ https://www.ncbi.nlm.nih.gov/pubmed/36482636 http://dx.doi.org/10.1097/MD.0000000000032022 |
work_keys_str_mv | AT tangxinliang efficacyandsafetyofhifuincombinationwithtaceinunresectablepediatrichbarandomizedcontrolledsinglecenterclinicaltrial AT hexiaobing efficacyandsafetyofhifuincombinationwithtaceinunresectablepediatrichbarandomizedcontrolledsinglecenterclinicaltrial AT jianghan efficacyandsafetyofhifuincombinationwithtaceinunresectablepediatrichbarandomizedcontrolledsinglecenterclinicaltrial |